electroCore (electroCore) ROCE % : -219.29% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is electroCore ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. electroCore's annualized ROCE % for the quarter that ended in Mar. 2024 was -219.29%.

electroCore ROCE % Historical Data

The historical data trend for electroCore's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

electroCore ROCE % Chart

electroCore Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-95.08

-93.50

-63.65

-83.09

-150.01

electroCore Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-164.36	-198.54	-171.50	-161.72	-219.29

electroCore ROCE % Calculation

electroCore's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-19.269	/	( ( (24.756 - 7.045)	+	(16.102 - 8.123) )	/ 2 )
	=	-19.269	/	( (17.711	+	7.979)	/ 2 )
	=	-19.269	/	12.845
	=	-150.01 %

electroCore's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-15.396	/	( ( (16.102 - 8.123)	+	(13.89 - 7.827) )	/ 2 )
	=	-15.396	/	( ( 7.979	+	6.063 )	/ 2 )
	=	-15.396	/	7.021
	=	-219.29 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

electroCore (NAS:ECOR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

electroCore ROCE % Related Terms

Thank you for viewing the detailed overview of electroCore's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

electroCore (electroCore) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » electroCore Inc (NAS:ECOR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Forge Way, Suite 205, Rockaway, NJ, USA, 07866

Website

https://www.electrocore.com

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients. The gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache, Bronchoconstriction and Medication Overuse Headache in adults.

Executives

Daniel S Goldberger	director, officer: Chief Executive Officer	24 CARPENTER ROAD, CHESTER NY 10918
Joseph P Errico	director, 10 percent owner, officer: See Remarks	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Thomas J. Errico	director, 10 percent owner	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 97920
Trevor J Moody	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
John P Gandolfo	director	62 TERRACE ROAD, WAYNE NJ 07470
Julie Ann Goldstein	director	205 FORGE WAY, ROCKAWAY NJ 07866
Patricia Wilber	director	205 FORGE WAY, SUITE 205, ROCKAWAY NJ 07866
Brian M Posner	officer: Chief Financial Officer	1590 REED ROAD, PENNINGTON NJ 08534
Tullis James L L	director	100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Thomas M Patton	director	C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
F Peter Cuneo	director	10 EAST 40TH ST, NEW YORK NY 10016
Stephen Ondra	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Nicholas Colucci	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Michael G Atieh	director	MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
Carrie Smith Cox	director	SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033